The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Drug Updates

Drug Updates

January 1, 2009 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Clinical Presentation and Drug Characteristics

Patients may present with mild fatigue to fulminant rhabdomyolysis requiring hospitalization. The most common symptoms are myalgia, weakness, low back and proximal muscle pain or generalized body aches, and/or dyspnea.4 Fatigue and muscle pain are often the most common chief complaint for statin-induced rhabdomyolysis, as are a subacute progression of low back pain and proximal muscle pain over the ensuing weeks.1,4 A high index of suspicion is necessary for any patient presenting with an elevated CK. The time of statin use before the development of rhabdomyolysis can range from one week to four years, the average being about six months to one year.1,4 This timeframe is shortened when a statin is combined with a fibrate, with an average onset of 32 days.4

You Might Also Like
  • Drug Updates: Citalopram hydrobromide, Statins, and More
  • Drug Updates
  • Rheumatology Drug Updates
Explore This Issue
January 2009
Also By This Author
  • Tofacitinib Promising for Psoriatic Arthritis & FDA Issues Alert for Warning for Saxagliptin & Alogliptin Diabetes Treatments

Statin pharmacodynamics and pharmacokinetics may play a role in the incidence of myopathy.1,7,8 Lovastatin, simvastatin, and atorvastatin are predominantly metabolized by the hepatic microsomal cytochrome (CYP) 450 3A4 system (simvastatin also has some CYP 3A5 metabolism). Both rosuvastatin and fluvastatin are also metabolized via the CYP450 2C9 system, with fluvastatin having some involvement of CYP 3A4 activity. Pravastatin undergoes sulfation and is hydrophilic lending to a lower risk of myopathy.1,7,8 Concurrent administration of a statin with other drugs metabolized by the same CYP450 isozyme leads to higher statin levels and a greater risk of myopathy.1,9 Many drugs which are substrates for the CYP3A4 isozyme and therefore many potential interactions can occur. Drugs with interactions include the following: fibrates (gemfibrozil > fenofibrate), nicotinic acid, cyclosporine, tacrolimus, azoles, macrolides (erythromycin, clarithromycin), protease inhibitors, verapamil, amiodarone, warfarin, fluoxetine, and diazepam.1,7,9 These agents should be used cautiously along with statins.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Because pravastatin and rosuvastatin are more hydrophilic than other statins, they are thought to have lower myopathy risks, but still cause myopathy.1,4,7,10 Since rosuvastatin is a relatively new agent, there are limited data on it.7 The choice of a statin may be more important in patients with moderate to severe renal dysfunction, since this is also a risk factor for myopathy. Both atorvastatin and fluvastatin have minimal renal excretion.1 Other risk factors for statin myopathy include excessive alcohol consumption, cocaine use, strenuous exercise, grapefruit juice ingestion (>1 quart/day), age over 80 years, hypertension, diabeties, a low body mass index, hypothyroidism, hypertriglyceridemia, hepatic disease, genetic polymorphisms of CYP450 isozymes, multisystem disease, among others.1,4,9 Certain genetic determinants may be associated with statin-associated myopathy risk.9,11

Pipeline Update

In February 2008, a Biological Product License Application (BLA) was submitted to the U.S. Food and Drug Administration (FDA) for the pegylated anti–tumor necrosis factor (TNF)-α monoclonal antibody (MAb), certolizumab pegol (Cimzia), for treating rheumatoid arthritis (RA).12 In April 2008, the agent received FDA approval for treating adults with moderate to severe Crohn’s disease.13 UCB has commenced efforts to develop additional rheumatology indications for certolizumab pegol.14 A pooled safety analysis from the certolizumab studies noted a low incidence of injection site pain and therapy discontinuations due to adverse drug reactions. Common side effects were headache, nasopharyngitis, and upper respiratory infections. A drug application for RA was accepted for review in both Canada and Europe in early 2008.15

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 | Single Page

Filed Under: Drug Updates, Safety Tagged With: Labeling Changes, Myopathy, Pharmaceutical Research, SafetyIssue: January 2009

You Might Also Like:
  • Drug Updates: Citalopram hydrobromide, Statins, and More
  • Drug Updates
  • Rheumatology Drug Updates
  • Drug Updates

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)